Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

2.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.1K
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

6.7K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
6.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

142
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
142
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

114
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
114

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reirradiation Options for Previously Irradiated Prostate Cancer: Is It Feasible to Randomise Between Treatment With Stereotactic Body Radiotherapy (SBRT) Versus High-Dose-Rate Brachytherapy?

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

The Use of Radiotherapy in the Cure of Different Cancers - Further Results From the FORTY (Favourable Outcomes From RadioTherapY) Project.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Best Practice for Patient-centred Radiotherapy in Clinical Trials and Beyond-A National Multidisciplinary Consensus.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

OSAIRIS: Lessons Learned From the Hospital-Based Implementation and Evaluation of an Open-Source Deep-Learning Model for Radiotherapy Image Segmentation.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

The Evolving Role of Novel Imaging Techniques for Radiotherapy Planning.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

The UK Divide: Does Having a Pembrolizumab-Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in Scotland.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024

Related Experiment Video

Updated: Apr 7, 2026

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

7.4K

Incorporating Genetic Biomarkers into Predictive Models of Normal Tissue Toxicity.

G C Barnett1, S L Kerns2, D J Noble1

  • 1Oncology Centre, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|July 14, 2015
PubMed
Summary
This summary is machine-generated.

Measuring individual normal tissue radiosensitivity can personalize radiotherapy. Genetic testing and assays can predict patient response, reducing toxicity and improving treatment outcomes for many.

Keywords:
GWASSNPnormal tissueradiosensitivityradiotherapy

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

936

Related Experiment Videos

Last Updated: Apr 7, 2026

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

7.4K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

936

Area of Science:

  • Oncology
  • Radiotherapy
  • Genetics

Background:

  • Radiotherapy toxicity varies significantly among patients due to differences in normal tissue radiosensitivity.
  • While rare syndromes impact radiosensitivity, non-syndromic variations can lead to a ±20% dose difference.
  • Personalized radiotherapy requires accurate measurement of individual radiosensitivity.

Purpose of the Study:

  • To explore methods for measuring individual normal tissue radiosensitivity.
  • To assess the potential of in vitro assays and genetic variation for predicting patient response to radiotherapy.
  • To evaluate the impact of personalized radiotherapy on toxicity and treatment efficacy.

Main Methods:

  • Review of early in vitro cellular radiosensitivity studies.
  • Evaluation of lymphocyte apoptosis assays for prospective validation.
  • Analysis of genome-wide association studies (GWAS) for genetic associations with radiotherapy toxicity.

Main Results:

  • Early in vitro studies showed equivocal links between cellular radiosensitivity and tissue response.
  • Lymphocyte apoptosis assays show promise for validating individual radiosensitivity.
  • GWAS reveal significant associations between genetic variations and radiotherapy toxicity, supporting future genetic testing.

Conclusions:

  • Individual normal tissue radiosensitivity can be measured using assays and genetic testing.
  • Personalized radiotherapy, incorporating genetic data, can reduce toxicity in radiosensitive patients and allow dose escalation in resistant individuals.
  • This approach has the potential to improve outcomes for approximately half of patients undergoing radical radiotherapy.